# MRT-6160 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mrt-6160

> MRT-6160, sponsored by Monte Rosa Therapeutics, Inc. (GLUE): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MRT-6160 |
| Codes | MRT-6160, DDY391 |
| Sponsor | Monte Rosa Therapeutics, Inc. (GLUE) https://sec-api.dev/companies/glue/catalysts |
| Indications | [sjögren's disease](https://sec-api.dev/indications/sjogren-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q1 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-01-10, last confirmed 2025-01-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003776): "Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025" https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-ex99_1.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2026-01-07, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336681): "Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of the VAV1-directed MGD MRT-6160 (DDY391) in immune-mediated diseases in 2026." https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210298): "Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026." https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-109353): "Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026." https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-005420): "Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026." https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm

### September 8, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: Sjögren's disease.
- First seen 2026-09-08, last confirmed 2026-09-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-384360): "BOSTON, Mass., September 8, 2026 - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with Sjögren's disease (SjD), the second most prevalent rheumatic autoimmune disease1." https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mrt-6160.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MRT-6160 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mrt-6160

```bibtex
@misc{secapidev_pdufa_mrt_6160_20261116,
  title        = {MRT-6160 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mrt-6160}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mrt_6160_20261116","title":"MRT-6160 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mrt-6160","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
